UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	/AL
OMB Number:	3235-0287
Estimated average but	rden
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* DANIELS BRIAN (Last) (First) (Middle) C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600			2. Issuer Name and Ticker or Trading Symbol Cabaletta Bio, Inc. [CABA] 3. Date of Earliest Transaction (Month/Day/Year) 06/01/2021						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director					
								-					<u> </u>	
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year) 06/03/2021				_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
PHILADELPHIA, PA 19104 (City) (State) (Zip)				Table I - Non-Derivative Securities Acou					s Acquired	 nred, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year		2A. Deemed Execution Date, if		3. Tra	nsaction 4	4. Securities Acquired		5. Amount of Securities Beneficially		eneficially d	6. 7. Nat Ownership of Ind	eneficial		
			(Month	onth/Day/Year)		de V	(A) or (D)	(Ins	str. 3 and 4)		0	Direct (D) or Indirect (I) (Instr. 4)	Ownership Instr. 4)	
Reminder:	Report on a s	•					in this	s who respon form are not re s a currently	equired to	respond	unless the		ed SEC 14	74 (9-02)
Reminder:	Report on a s	•												74 (0 00)
Title of Derivative	2. Conversion		3A. Deemed Execution Date, if	4. Transac	ts, call 5. tion of	, warrants Number Derivative	in this display uired, Display, options, co	form are not rest a currently seed of, or Benevare tible secure ercisable and Date	equired to valid OME eficially Ow ities) 7. Title an of Underly	o respond 3 control re vned ad Amount ying	8. Price of Derivative	9. Number of Derivative	f 10. Ownership	11. Nati
1. Title of	2. Conversion		3A. Deemed Execution Date, if	4. Transac Code	tion of A of (I	, warrants Number	in this display uired, Display options, co	form are not rest a currently seed of, or Benevare tible secure ercisable and Date	equired to valid OME eficially Ow ities) 7. Title an	o respond 3 control r vned ad Amount ying	unless the number.	9. Number of Derivative Securities Beneficially Owned Following Reported Transactions	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect (s) (I)	Benefic Owners (Instr. 4
Title of Derivative Security	2. Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion of A of (I	Number Derivative curities equired (A) Disposed (D) sist. 3, 4, d 5)	in this display uired, Display options, co	form are not rest a currently was a currently was a currently was a currently was a currently and one of the currently and the currently a	equired to valid OME eficially Ow ities) 7. Title an of Underly Securities	o respond 3 control r vned ad Amount ying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nation of Indirection of Section 11. Nation of Indirection Owners (Instr. 4

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
DANIELS BRIAN C/O CABALETTA BIO, INC. 2929 ARCH STREET, SUITE 600 PHILADELPHIA, PA 19104	X					

Signatures

/s/ Steven Nichtberger, Attorney-in-Fact	06/28/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This option shall vest in accordance with the following schedule: (1) 25% of the shares subject to the option shall vest on June 24, 2022 and (2) the remaining 75% of the shares subject to the option shall vest in equal quarterly installments over the next 3 years, subject to the Reporting Person's continued service relationship with the Issuer.

Remarks:

This Form 4 is being filed to amend the vesting terms of this grant. The amended vesting term is listed in Footnote #1.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.